Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus Clinical Trial
Official title:
A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus
| Verified date | February 2021 |
| Source | Dompé Farmaceutici S.p.A |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8. This study is designed to explore the efficacy of reparixin in preventing graft dysfunction after islet transplantation in type 1 diabetes patients (T1D).
| Status | Completed |
| Enrollment | 9 |
| Est. completion date | April 30, 2013 |
| Est. primary completion date | April 30, 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility | Inclusion criteria: - Ages 18-65 years, inclusive. - Patients eligible for pancreatic islet transplantation based on local accepted practice and guidelines. This includes at least: a)clinical history compatible with T1D with insulin-dependence for >5 years; b) undetectable stimulated (arginine or MMTT) C-peptide levels (<0.3 ng/mL) in the 12 months before transplant. Sites will comply with any additional or more stringent criteria locally accepted, as per centre practice. - Patients with adequate renal reserve as per calculated creatinine clearance (CLcr) > 60 mL/min according to the Cockcroft-Gault formula (1976). - Planned intrahepatic islet transplantation alone from a non-living donor with brain death. - Planned infusion of 4000 to 7000 islet equivalent (IEQ)/kg body weight. - Patients willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations. - Patients given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. Exclusion criteria: - Recipients of any previous transplant, except from recipients of a previous pancreatic islet transplantation that has failed, are off immunosuppression since at least 1 year and have negative anti-HLA. - Recipients of islet from a non-heart beating donor. - A body mass index >30 kg/m2 or patient weight <45 kg. - Pre-transplant average daily insulin requirement >1 IU/kg/day. - Pre-transplant HbA1c >11%. - Patients with hepatic dysfunction as defined by increased ALT/AST > 3 x ULN and increased total bilirubin > 3mg/dL [>51.3 micromol/L]). - Patients who receive treatment for a medical condition requiring chronic use of systemic steroids. - Treatment with any anti-diabetic medication other than insulin within 4 weeks of transplant. - Use of any investigational agent within 4 weeks of enrolment. - Hypersensitivity to: - ibuprofen or to more than one non steroidal anti-inflammatory drug - medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib. - Pregnant or breast-feeding women; unwillingness to use effective contraceptive measures (females and males). Sites will comply with any additional exclusion criteria locally accepted, as per centre practice. |
| Country | Name | City | State |
|---|---|---|---|
| Germany | University Hospital Carl Gustav Carus Dresden | Dresden | |
| Italy | Ospedale San Raffaele | Milan |
| Lead Sponsor | Collaborator |
|---|---|
| Dompé Farmaceutici S.p.A |
Germany, Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | The Percentage of Insulin-independent Patients Following Islet Cell Transplantation up to One Year After the Last Transplant | Insulin-independence was defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by:
HbA1c level of less than 7%; glucose level after an overnight fast not exceeding 140 mg/dL (7.8 mmol/L) more than 3 times a week (based on measuring capillary glucose level a minimum of 7 times in a 7-day period); glucose level not exceeding 2-hour postprandial levels of 180 mg/dL (10 mmol/L) more than 4 times a week (based on measuring capillary glucose level a minimum of 21 times in a 7-day period). |
up to one year after the transplant | |
| Other | Time to Achieve Insulin-independence After the Transplant 2 | Time to achieve insulin-independence after the transplant was defined as the number of days between islet infusion and onset of insulin-independence. This was calculated as: date of onset of insulin-independence minus the islet infusion date. | up to 1 year after transplant 2 | |
| Other | Total Time of Insulin Independence After the Transplant | Total time of insulin-independence after the transplant. This was defined as the number of days between the onset and loss of insulin-independence and was calculated as the date of loss of insulin-independence minus the date of onset of insulin-independence.
Of the 3 patients who achieve insulin-independence after transplant 2, only 2 remained insulin-independent up to 1 year and the mean (SD) total time of insulin-independence after the second transplant was 276 (96.2) days with a range between 208 and 344 days. |
up to 1 year after transplant 2 | |
| Other | Absolute Change in Average Daily Insulin Requirements From Pre-transplant Levels | Daily insulin requirement was calculated as the average requirement over the previous week (seven days). | Months 1, 3, 6, 12 post-transplant | |
| Other | Percentage Change in Average Daily Insulin Requirements From Pre-transplant Levels | Daily insulin requirement was calculated as the average requirement over the previous week (seven days). | Months 1, 3, 6, 12 post-transplant | |
| Other | Absolute Change in Fasted HbA1c From Pre-transplant Levels | The absolute change between the time-point value and baseline value. | Months 1, 3, 6, 12 post-transplant | |
| Other | Percentage Change in Fasted HbA1c From Pre-transplant Levels | The absolute percentage between the time-point value and baseline value. | Months 1, 3, 6, 12 post-transplant | |
| Other | The Percentage of Patients Free of Hypoglycaemic Events With Reduced Awareness | Reduced awareness is defined as a reduced ability to recognize symptoms of hypoglycemia, sometimes referred to as "hypoglycemia unawareness". | Months 1, 3, 6, 12 post-transplant | |
| Other | Number of Participants With Adverse Events by Severity and With Serious Adverse Events | Safety was assessed by monitoring the incidence and severity of adverse events (AEs) and serious AEs (SAEs) throughout the study up to 1 year after last transplant.
A serious adverse event is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. |
up to 1 year after transplant | |
| Other | AUC (-10 to 120 Minutes Post-dose) of Glucose Derived From Mixed Meal Tolerance Test (MMTT) at 1, 3, 6 and 12 Months Post-transplant | Glucose level reflects the metabolic control. The MMTT was performed after an overnight fast, at baseline (within 1 week prior to randomization), and at each of the following timepoints.
AUC was calculated using the trapezoidal rule. |
-10 to 120 Minutes Post-dose at Months 1, 3, 6, 12 post-transplant | |
| Other | AUC (-10 to 120 Minutes Post-dose) of C-peptide Derived From Mixed Meal Tolerance Test (MMTT) at 1, 3, 6 and 12 Months Post-transplant | C-peptide level is an indirect measure of pancreatic beta-cell function. The MMTT was performed after an overnight fast, at baseline (within 1 week prior to randomization), and at each of the following timepoints.
AUC was calculated using the trapezoidal rule. |
-10 to 120 Minutes Post-dose at Months 1, 3, 6, 12 post-transplant | |
| Other | AUC (-10 to 120 Minutes Post-dose) of Insulin Derived From Mixed Meal Tolerance Test (MMTT) at 1, 3, 6 and 12 Months Post-transplant | Insulin level is a direct measure of pancreatic beta-cell function. The MMTT was performed after an overnight fast, at baseline (within 1 week prior to randomization), and at each of the following timepoints.
AUC was calculated using the trapezoidal rule. |
-10 to 120 Minutes Post-dose at Months 1, 3, 6, 12 post-transplant | |
| Other | AUC(-10 to 120 Min Post Dose)/IEQ/kg for C Peptide Derived From Mixed Meal Tolerance Test (MMTT) at 1, 3, 6 Months Post-transplant 1 | For Transplant 1 (patients on reparixin), the mean C-Peptide AUC (derived from the MMTT) corrected by IEQ/kg values were calculated.
AUC was calculated using the trapezoidal rule and normalized by the actual number of islet equivalents (IEQ) per kilo infused (IEQ/kg). |
-10 to 120 Minutes Post-dose at Months 1, 3, 6, 12 post-transplant | |
| Other | The Percentage of Patients Free of Severe Hypoglycaemic Events | A severe hypoglycemic event is defined as an event with one of the following symptoms: "memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms", in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration. | Months 1, 3, 6, 12 post-transplant | |
| Other | Beta-cell Function as Assessed by Beta-score | The beta-score provides a simple clinical scoring system that encompasses glycemic control, diabetes therapy, and endogenous insulin secretion that correlates well with physiological measures of beta-cell function. On this basis, it is suitable as an overall measure of beta-cell transplant function.
Beta score is a composite scoring system based on fasting plasma glucose values, HbA1c, insulin independence or use of insulin/OHAs, and the determination of stimulated C-peptide levels. Normal values are given a score of 2, intermediate values merit a score of 1, and clearly abnormal values garner no points. Thus, a perfect score is 8, and a score of 0 indicates absolute absence of beta-cell function. |
Months 1, 3, 6, 12 post-transplant | |
| Other | Beta-cell Function as Assessed by TEF/IEQ/kg Ratio | The TEF/IEQ/kg ratio is a parameter to assess transplant efficiency corrected by the number of transplanted islets. | At months 1, 3, 6 after transplant 1 and months 1,3, 6, and 12 after transplant 2 | |
| Other | Serum Level of Alanine Amino Transferase (ALT) | ALT is commonly measured clinically as part of liver function tests. | Pre-transplant and at days 1-7 and months 1 and 3 post-transplant | |
| Other | Serum Level of Aspartate Amino Transferase (AST) | AST is commonly measured clinically as part of liver function tests. | Pre-transplant and at days 1-7 and months 1 and 3 post-transplant | |
| Other | Change From Pre-transplant in Cytokine Levels - CXCL8 | Time course of inflammatory chemokines/cytokines as assessed by serum levels of CXCL8 (CXC ligand 8 [formerly interleukin (IL)-8]) (time frame: 0, 6, 12, 24, 72, 120, and 168 hours after islet infusion). | 6, 12, 24, 72, 120, and 168 hours post-transplant 1 | |
| Other | Change From Pre-transplant in Cytokine Levels - CXCL1 | Time course of inflammatory chemokines/cytokines as assessed by serum levels of CXCL1 (time frame: 0, 6, 12, 24, 72, 120, and 168 hours after islet infusion). | 6, 12, 24, 72, 120, and 168 hours post-transplant 1 | |
| Other | Change From Pre-transplant in Cytokine Levels - IL-6 | Time course of inflammatory chemokines/cytokines as assessed by serum levels of interleukin 6 (IL-6) (time frame: 0, 6, 12, 24, 72, 120, and 168 hours after islet infusion). | 6, 12, 24, 72, 120, and 168 hours post-transplant 1 | |
| Primary | The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5 | Insulin-independence was defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by:
HbA1c level of less than 7%; glucose level after an overnight fast not exceeding 140 mg/dL (7.8 mmol/L) more than 3 times a week (based on measuring capillary glucose level a minimum of 7 times in a 7-day period); glucose level not exceeding 2-hour postprandial levels of 180 mg/dL (10 mmol/L) more than 4 times a week (based on measuring capillary glucose level a minimum of 21 times in a 7-day period). |
day 75 +/- 5 post-transplant |